Clinical study for Qing Bu Weijing decoction in improving airway mucus hypersecretion to reduce acute exacerbation of bronchiectasis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021941

Enrollment

Unknown

Registered

2019-03-17

Start date

2019-03-16

Completion date

Unknown

Last updated

2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Interventions

test group:Qing Bu Weijing decoction

Control group:Carboxymethorin oral solution

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Outpatients who meet the diagnostic criteria for bronchiectasis; (2) No smoking within 1 year prior to enrollment, sputum >30 ml per day, and no acute exacerbations due to medical history and physical examination; (3) Aged 18-70 years; (4) TCM syndrome differentiation is qi and yin deficiency, phlegm and heat accumulation; (5) Patients who have at least 3 acute exacerbations in the past year; (6) Those who are willing to follow the doctor's diagnosis and treatment arrangements and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Those who do not meet the above criteria for Western medicine diagnosis and TCM syndrome differentiation, patients with dry bronchitis as the main manifestation of hemoptysis; (2) Those who have changed their condition within 4 weeks before enrollment; (3) Pregnant women or lactating women (4) Chronic alcohol abuse history or history of drug abuse or any factors that affect compliance; (5) Patients with severe heart, cerebrovascular, liver, kidney and hematopoietic system, peptic ulcer and other primary diseases; (6) Abnormal liver and kidney function: liver (ALT or AST) more than double the upper limit of normal value or abnormal renal function (BUN or Cr); (7) Psychotic patients; (8) Allergic and allergic to the drug; (9) Those who have participated in other clinical trials within a month; (10) Other circumstances that the investigator considers unfit for inclusion.

Design outcomes

Primary

Measure	Time frame
The number of acute exacerbations of bronchiectasis;CASA-Q score;	—

Secondary

Measure	Time frame
Quantitative symptom score;Pulmonary function;Chest CT scan;IL-8;IL-10;Neutrophil elastase;	—

Countries

China

Contacts

Public ContactWang Bing

Xiyuan Hospital, China Academy of Chinese Medical Sciences

angeline1019@126.com+86 13426459995

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026